

Therapeutisches Drug-Monitoring (TDM) von Psychopharmaka

Dr. Daniel Müller, Institut für Klinische Chemie, Universitätsspital Zürich

Prof. Dr. sc. nat. Katharina Rentsch, Klinische, Chemie, Universitätsspital Basel

Referenzen

1. Andrade C. Schizophrenia and smoking. *J Clin Psychiatry*. 2012 Jun;73(6):e725-7.
2. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. *Pharmacopsychiatry*. 2011 Sep;44(6):195-235.
3. Ostad Haji E, Mann K, Dragicevic A, Muller MJ, Boland K, Rao ML, et al. Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. *Ther Drug Monit*. 2013 Jun;35(3):396-401.
4. Laizure SC, DeVane CL. Stability of bupropion and its major metabolites in human plasma. *Ther Drug Monit*. 1985;7(4):447-50.
5. Secilir A, Schrier L, Bijleveld YA, Toersche JH, Jorjani S, Burggraaf J, et al. Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2013 Apr 1;923-924:22-8.